The news of Morgan Stanley reiterating an Equal-Weight rating on Ascendis Pharma and maintaining a $109 price target is neutral for the stock price in the short term. The rating suggests that the stock is fairly valued and the price target remains unchanged, indicating no significant change in the analyst's outlook.